AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) announced the commencement of ImmunoPass clinical trials. ImmunoPass is AXIM’s rapid point-of-care diagnostic test measuring neutralizing antibody levels to COVID-19.
ImmunoPass to help in measuring neutralizing antibody levels
Immunity monitoring is becoming a critical role in determining vaccines’ effectiveness, and COVID-19 vaccinations campaigns begin. Since immunity against the virus is not something that will last forever, immunity monitoring will go on for years, even with mass vaccination globally. Therefore, neutralizing antibodies measuring in people with received jabs will offer insight into how the vaccine responds over time. This way, researchers can know when the neutralizing antibodies dip, thus the need for revaccination.
As a result, AXIM developed the rapid diagnostic test, ImmunoPass, to address this shortcoming. ImmunoPass focuses on measuring functional neutralizing antibody levels against SARS-CoV-2. Most importantly, ImmunoPass has demonstrated considerable statistical correlation with the coronavirus neutralizing assay compared to available antibody tests. Therefore, ImmunoPass could be an effective, low-cost option to lab-based assays since it agrees with live virus-based assays, in monition neutralizing antibodies in vaccine recipients.
AXIM® prints manuscript on ImmunoPass development
Recently the company released a manuscript blueprint detailing the development of ImmunoPass for semi-quantitative measuring of neutralizing antibodies to SARS-CoV-2. The manuscript is a product of several executives of the company’s subsidiary, sapphire Biotech Inc. including Chief Technology Officer Alim Seit-Nebi, Chief Scientific officer Sergei Svarovsky, and Chief Clinical Officer Douglas Lake.
AXIM CEO John Huemoeller said that the pandemic has resulted in significant social and economic unrest, including losing millions of people. He said that with vaccination campaigns rolling out, there is a need to monitor the protective neutralizing antibody levels. If there is a decline in vaccine-induced neutralizing antibodies, there is a need to have a vaccine booster to keep people protected and prevent virus spread. Huemoeller said that this is where the company’s ImmunoPass will help test to indicate an individual’s level of protection. He said that the point-of-care test is quick, affordable, accurate, and portable relative to currently available tests.
 Commences ImmunoPass Rapid Diagnostic Test Clinical Trials With Vaccinated People){kind=link}